NEW YORK — Drug discovery and development firm Crown Bioscience has partnered with Cambridge Quantum Computing (CQC) on the identification of novel cancer treatment biomarkers, the companies said on Wednesday.
Under the terms of the deal, the companies will combine UK-based CQC's quantum machine algorithms and software development capabilities with CrownBio's preclinical and translational research expertise and datasets to identify multi-gene biomarkers that can be used in cancer drug discovery.
Additional terms were not disclosed.
"The agreement continues CrownBio's commitment to innovation and the application of technology to accelerate and de-risk drug development, leading to stronger drug candidates and a more rapid transition from preclinical phases to the clinic," CrownBio CE Armin Spura said in a statement.
San Diego-based CrownBio is a unit of JSR Life Sciences.